Page 5 - ஸ்டான்போர்ட் புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Candidate therapeutics tested for TH4 subtype in IU-TAB-1 cell line. Experimental dose-response curves assessing relative growth (Hoechst staining of DNA), proliferation (Ki67), viability (DRAQ7 assay), and apoptosis (caspase) for (A). view more  Credit: Correspondence to - Sukhmani K. Padda - sukhmani.padda@cshs.org Six novel molecular subtypes of TETs from the TCGA were identified, and there was no association with WHO histologic subtype. The IU-TAB-1 cell line clustered into the TH4 molecular subtype and in vitro testing of candidate therapeutics was performed. Sensitivity to nelfinavir was due to the IU-TAB-1 cell line s gain-of function mutation in PIK3CA and amplification of genes observed from array comparative genomic hybridization, including AURKA, ERBB2, KIT, PDGFRA and PDGFB, that are known upregulate AKT, while resistance to everolimus was primarily driven by upregulation of downstream signaling of KIT, PDGFRA and PDGFB in the presence of mT

Sukhmanik paddaOncotarget research outputImpact journalsPadda research teamWorld health organizationCancer genome atlasStanford university schoolStanford cancer instituteஒலி கிளவுட்தாக்கம் பத்திரிகைகள்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்புற்றுநோய் மரபணு அட்லஸ்ஸ்டான்போர்ட் பல்கலைக்கழகம் பள்ளிஸ்டான்போர்ட் புற்றுநோய் நிறுவனம்